Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized placebo-controlled abatacept induction study in ulcerative colitis
2006-003604-19Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2006
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of abatacept in autoimmune colitis (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Clinical response at Day IP-85 (abatacept 30/~10 mg/kg vs placebo) and Clinical response at Day IP-85 (abatacept ~10 mg/kg vs placebo). Started Dec 2006; status: terminated.
02
Drugs
abatacept
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2006-003604-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003604-19.